“This preclinical work will help strengthen Emyria’s intellectual property relating to our synthetic cannabinoid platform. Importantly, this work will.
Emyria Ltd (ASX:EMD) s Michael Winlo tells Proactive s Andrew Scott they ve contracted a leading North American drug manufacturer to deliver a range of.